315 related articles for article (PubMed ID: 11286307)
1. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated?
Lopaschuk GD
Coron Artery Dis; 2001 Feb; 12 Suppl 1():S8-11. PubMed ID: 11286307
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.
Lopaschuk GD; Barr R; Thomas PD; Dyck JR
Circ Res; 2003 Aug; 93(3):e33-7. PubMed ID: 12869392
[TBL] [Abstract][Full Text] [Related]
3. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation.
Dyck JR; Cheng JF; Stanley WC; Barr R; Chandler MP; Brown S; Wallace D; Arrhenius T; Harmon C; Yang G; Nadzan AM; Lopaschuk GD
Circ Res; 2004 May; 94(9):e78-84. PubMed ID: 15105298
[TBL] [Abstract][Full Text] [Related]
4. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
Kantor PF; Lucien A; Kozak R; Lopaschuk GD
Circ Res; 2000 Mar; 86(5):580-8. PubMed ID: 10720420
[TBL] [Abstract][Full Text] [Related]
5. Trimetazidine normalizes postischemic function of hypertrophied rat hearts.
Saeedi R; Grist M; Wambolt RB; Bescond-Jacquet A; Lucien A; Allard MF
J Pharmacol Exp Ther; 2005 Jul; 314(1):446-54. PubMed ID: 15840766
[TBL] [Abstract][Full Text] [Related]
6. Metabolic energy metabolism in diabetes: therapeutic implications.
Pogatsa G
Coron Artery Dis; 2001 Feb; 12 Suppl 1():S29-33. PubMed ID: 11286305
[TBL] [Abstract][Full Text] [Related]
7. The effects of chronic trimetazidine treatment on mechanical function and fatty acid oxidation in diabetic rat hearts.
Onay-Besikci A; Guner S; Arioglu E; Ozakca I; Ozcelikay AT; Altan VM
Can J Physiol Pharmacol; 2007 May; 85(5):527-35. PubMed ID: 17632588
[TBL] [Abstract][Full Text] [Related]
8. Targets for modulation of fatty acid oxidation in the heart.
Lopaschuk GD
Curr Opin Investig Drugs; 2004 Mar; 5(3):290-4. PubMed ID: 15083595
[TBL] [Abstract][Full Text] [Related]
9. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism.
Lopaschuk GD
Am J Cardiol; 1998 Sep; 82(5A):14K-17K. PubMed ID: 9737481
[TBL] [Abstract][Full Text] [Related]
10. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
MacInnes A; Fairman DA; Binding P; Rhodes Ja; Wyatt MJ; Phelan A; Haddock PS; Karran EH
Circ Res; 2003 Aug; 93(3):e26-32. PubMed ID: 12869391
[TBL] [Abstract][Full Text] [Related]
11. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion.
Wang P; Fraser H; Lloyd SG; McVeigh JJ; Belardinelli L; Chatham JC
J Pharmacol Exp Ther; 2007 Apr; 321(1):213-20. PubMed ID: 17202401
[TBL] [Abstract][Full Text] [Related]
12. Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure.
Lopaschuk GD
Semin Cardiothorac Vasc Anesth; 2006 Sep; 10(3):228-30. PubMed ID: 16959756
[TBL] [Abstract][Full Text] [Related]
13. Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy.
Wenmeng W; Qizhu T
Med Hypotheses; 2011 Feb; 76(2):181-3. PubMed ID: 20932648
[TBL] [Abstract][Full Text] [Related]
14. [Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism].
Lopaschuk GD
Presse Med; 1998 Dec; 27(39):2100-4. PubMed ID: 9893703
[TBL] [Abstract][Full Text] [Related]
15. Energetic myocardial metabolism and oxidative stress: let's make them our friends in the fight against heart failure.
Scolletta S; Biagioli B
Biomed Pharmacother; 2010 Mar; 64(3):203-7. PubMed ID: 19954925
[TBL] [Abstract][Full Text] [Related]
16. Metabolic therapy for the treatment of ischemic heart disease: reality and expectations.
Wang W; Lopaschuk GD
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1123-34. PubMed ID: 18035928
[TBL] [Abstract][Full Text] [Related]
17. Cardioprotective effects of trimetazidine: a review.
Marzilli M
Curr Med Res Opin; 2003; 19(7):661-72. PubMed ID: 14606990
[TBL] [Abstract][Full Text] [Related]
18. ["Persistent" angina: rationale for a metabolic approach].
Marzilli M
Ital Heart J; 2004 Mar; 5 Suppl 2():37S-41S. PubMed ID: 15074776
[TBL] [Abstract][Full Text] [Related]
19. Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury.
Dyck JR; Hopkins TA; Bonnet S; Michelakis ED; Young ME; Watanabe M; Kawase Y; Jishage K; Lopaschuk GD
Circulation; 2006 Oct; 114(16):1721-8. PubMed ID: 17030679
[TBL] [Abstract][Full Text] [Related]
20. Cardiac energetics during ischaemia and the rationale for metabolic interventions.
Stanley WC
Coron Artery Dis; 2001 Feb; 12 Suppl 1():S3-7. PubMed ID: 11286306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
